NSG 552 Psychopharm Exam 3 2026 – 180+ Practice Questions on Substance Use Disorders, Dementia, ADHD & Personality Disorders

This comprehensive NSG 552 Psychopharm Exam 3 study guide contains over 180 high-yield practice questions and answers covering substance use disorders, addiction pharmacotherapy, neurocognitive disorders, ADHD, autism spectrum disorder, personality disorders, sexual dysfunction, and evidence-based psychopharmacologic interventions. Designed for Psychiatric Mental Health Nurse Practitioner (PMHNP) students and advanced practice providers, this resource transforms complex psychiatric concepts into an active recall format that strengthens clinical judgment, enhances prescribing confidence, and improves performance on graduate psychopharmacology examinations and PMHNP certification assessments. The material integrates DSM-5 diagnostic principles, medication mechanisms of action, therapeutic decision-making, safety monitoring, and guideline-based recommendations frequently emphasized in advanced psychiatric nursing curricula. The substance use disorders section provides an in-depth review of intoxication, withdrawal syndromes, and the neurobiology of addiction. Students will strengthen their understanding of dopamine-mediated reward pathways, nucleus accumbens activation, and DSM-5 criteria used to classify mild, moderate, and severe substance use disorders. Comprehensive coverage includes alcohol, opioid, cocaine, cannabis, nicotine, caffeine, and benzodiazepine-related disorders, allowing learners to recognize hallmark clinical manifestations and differentiate intoxication from withdrawal presentations frequently encountered in psychiatric and emergency settings. Alcohol use disorder management is explored extensively through evidence-based detoxification and relapse prevention strategies. Learners will review the use of the Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar), identify symptoms associated with mild, moderate, and severe alcohol withdrawal, and recognize life-threatening complications including seizures and delirium tremens. The guide examines FDA-approved medications for alcohol use disorder, including acamprosate, naltrexone, and disulfiram, while integrating patient education regarding aversion therapy, abstinence requirements, hepatic considerations, and the prevention of Wernicke-Korsakoff syndrome through thiamine replacement. The opioid use disorder component delivers detailed coverage of overdose recognition, withdrawal management, and medication-assisted treatment. Students will strengthen their understanding of naloxone, methadone, buprenorphine, naltrexone, and supportive medications used to manage withdrawal symptoms. Emphasis is placed on Clinical Opioid Withdrawal Scale (COWS) interpretation, induction timing considerations, mechanisms of action, federal prescribing requirements, and the role of medication-assisted treatment in reducing relapse and mortality. Additional substance-related content reviews evidence-based approaches to cocaine use disorder, cannabis intoxication, tobacco dependence, and nicotine replacement therapies. Students will examine off-label treatment considerations, smoking cessation strategies involving bupropion and varenicline, cardiovascular risks associated with stimulant use, and the importance of psychotherapy and behavioral interventions in long-term recovery planning. The neurocognitive disorders section provides a comprehensive review of delirium, Alzheimer's disease, Lewy body dementia, frontotemporal degeneration, and age-related psychopharmacologic considerations. Learners will evaluate neurotransmitter abnormalities underlying dementia syndromes, distinguish acute delirium from progressive neurocognitive decline, and identify reversible causes of altered cognition. Pharmacologic management strategies involving cholinesterase inhibitors, NMDA receptor antagonists, atypical antipsychotics, SSRIs, and adjunctive therapies are integrated with discussions of Beers Criteria, anticholinergic burden, polypharmacy, and safety concerns in geriatric populations. Students will gain an in-depth understanding of donepezil, rivastigmine, and memantine, including indications, mechanisms of action, adverse effect profiles, and appropriate patient selection. The guide further explores anticholinergic toxidrome recognition, dementia-related psychosis management, laboratory evaluation of neurocognitive disorders, and evidence-based interventions targeting agitation, aggression, insomnia, appetite loss, and depressive symptoms in older adults. Child and adolescent psychopharmacology concepts are examined extensively through detailed discussions of Attention-Deficit/Hyperactivity Disorder (ADHD), autism spectrum disorder, intellectual developmental disorder, conduct disorder, and enuresis. Students will review first-line stimulant therapies, atomoxetine, alpha-2 adrenergic agonists, monitoring requirements, contraindications, and strategies for managing adverse effects. Additional emphasis is placed on risperidone and aripiprazole use in autism spectrum disorder, behavioral interventions for intellectual developmental disorders, and symptom-targeted approaches to aggression, irritability, hyperactivity, and self-injurious behaviors. The personality disorders section reinforces the importance of psychotherapy as the foundation of treatment while examining adjunctive pharmacologic interventions for impulsivity, affective instability, and cognitive-perceptual disturbances. Learners will explore dialectical behavior therapy as the gold-standard treatment for Borderline Personality Disorder, identify medications requiring caution due to overdose risk or dependency potential, and strengthen their understanding of patient-centered prescribing in complex psychiatric populations. Comprehensive coverage of psychosexual dysfunction prepares students to recognize medication-induced sexual adverse effects, endocrine contributors, and evidence-based treatment options. Topics include antidepressant-associated sexual dysfunction, premature ejaculation, phosphodiesterase-5 inhibitors, libido modulation through serotonergic and dopaminergic pathways, and medication selection strategies that optimize adherence and quality of life. This study guide is particularly valuable for Psychiatric Mental Health Nurse Practitioner (PMHNP) students, Master of Science in Nursing (MSN) students, Doctor of Nursing Practice (DNP) students, psychiatric nursing students, advanced practice registered nurses, physician assistant students specializing in behavioral health, psychiatry residents, nurse practitioner certification candidates, and healthcare professionals seeking a focused review of advanced psychopharmacology principles. The content aligns with established evidence-based practice standards and authoritative references, including: Stahl, S. M. (2024). Stahl's Essential Psychopharmacology: Neuroscientific Basis and Practical Applications (6th ed.). Cambridge University Press. Stahl, S. M. (2024). Stahl's Essential Psychopharmacology Prescriber's Guide (8th ed.). Cambridge University Press. American Psychiatric Association. (2022). Diagnostic and Statistical Manual of Mental Disorders, Text Revision (DSM-5-TR). American Psychiatric Publishing. Sadock, B. J., Sadock, V. A., & Ruiz, P. (2022). Kaplan & Sadock's Synopsis of Psychiatry (12th ed.). Wolters Kluwer. Townsend, M. C., & Morgan, K. I. (2024). Psychiatric Mental Health Nursing: Concepts of Care in Evidence-Based Practice (11th ed.). F.A. Davis. Substance Abuse and Mental Health Services Administration (SAMHSA). Current recommendations for medication-assisted treatment and substance use disorder management. American Academy of Neurology (AAN). Evidence-based guidance for dementia evaluation and treatment. American Academy of Child and Adolescent Psychiatry (AACAP). Current recommendations regarding ADHD and pediatric psychopharmacology. Designed as both an intensive examination review and a practical psychopharmacology companion, this study guide promotes active learning, strengthens diagnostic reasoning, enhances medication safety awareness, and prepares learners to integrate evidence-based psychiatric treatment strategies into advanced clinical practice. Keywords: NSG 552, Psychopharm Exam 3, Advanced psychopharmacology, Substance use disorders, DSM-5 substance use disorder criteria, Intoxication, Withdrawal, Dopamine reward pathway, Nucleus accumbens, Alcohol use disorder, Alcohol withdrawal, Delirium tremens, CIWA-Ar, Wernicke encephalopathy, Korsakoff syndrome, Acamprosate, Naltrexone, Disulfiram, Thiamine, Cocaine use disorder, Cannabis intoxication, Nicotine dependence, Smoking cessation, Varenicline, Bupropion, Nicotine replacement therapy, Opioid use disorder, Naloxone, Methadone, Buprenorphine, Suboxone, COWS, Medication-assisted treatment, Delirium, Neurocognitive disorders, Alzheimer's disease, Lewy body dementia, Frontotemporal degeneration, Donepezil, Rivastigmine, Memantine, Cholinesterase inhibitors, NMDA receptor antagonists, Beers Criteria, Polypharmacy, Anticholinergic toxidrome, Dementia-related psychosis, ADHD, Stimulants, Methylphenidate, Amphetamine salts, Atomoxetine, Clonidine, Guanfacine, Autism spectrum disorder, Risperidone, Aripiprazole, Intellectual developmental disorder, Conduct disorder, Enuresis, Imipramine, Borderline personality disorder, Dialectical behavior therapy, Personality disorders, Sexual dysfunction, PDE-5 inhibitors, Sildenafil, Tadalafil, Premature ejaculation, Paroxetine, Bupropion, PMHNP exam preparation, Psychiatric nursing review, Nurse practitioner certification review